Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab.
Bard
Susan
S
Paravisini
Alexandra
A
Avilés-Izquierdo
José Antonio
JA
Fernandez-Cruz
Eduardo
E
Sánchez-Ramón
Silvia
S
D000328:Adult; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004485:Eczema / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007589:Job Syndrome / Q000150:complications*; D000069444:Omalizumab; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E